Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Suven Life Sciences (Suven) has stated that the Canadian Patent Office has issued a third product patent no 2,507,923 and Eurasian Patent Office has granted sixth product patent no 12750 corresponding to the new chemical entity (NCE) for the treatment of disorders associated with neurodegenerative diseases and these patents are valid until 2023 and 2025 respectively.
Subscribe to our email newsletter
Suven said that the granted claims of the patents include the class of selective 5-HT compounds discovered by it and are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimer’s, ADHD, Parkinson, Schizophrenia and Huntington’s diseases.
Suven claimed that these issued patents are for the same inventions that of the granted patents in various other countries like USA, Europe etc for their NCE. Products out of these inventions may be out-licensed at various stages of clinical development like at Phase I or Phase II.
Venkat Jasti, CEO of Suven, said: “We are very pleased by the grant of these 2 patents to Suven by Canadian Patent Office and Eurasian Patent Office for our pipeline of molecules in CNS arena that are being developed for cognitive disorders which has an estimated $20bn market.”